CRISPR Therapeutics AG (CRSP) EBIT Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed EBIT Margin across 11 years of filings, most recently posting 1151.84% for Q2 2026.

• In Q2 2026, EBIT Margin rose 2455713.0% year-over-year to 1151.84%; the TTM figure through Jun 2026 stood at 3989.99% (down 253805.0% YoY), while the FY2025 annual figure was 18933.65%, down 1768327.0% from the prior year.
• EBIT Margin came in at 1151.84% for Q2 2026 at CRISPR Therapeutics AG, up from 8933.33% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 34.58% in Q4 2023 to a low of 2192350.0% in Q4 2022.
• Average EBIT Margin over 5 years is 157800.01%, with a median of 17912.5% recorded in 2025.
• Year-over-year, EBIT Margin sank 219122047 bps in 2022 and surged 219238458 bps in 2023.
• Over 5 years, EBIT Margin stood at 2192350.0% in 2022, then surged by 100 bps to 34.58% in 2023, then plunged by 623 bps to 180.96% in 2024, then sank by 9798 bps to 17912.5% in 2025, then surged by 94 bps to 1151.84% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 1151.84% in Q2 2026, 8933.33% in Q1 2026, and 17912.5% in Q4 2025.